期刊文献+

亲缘外周造血干细胞移植治疗急性髓系白血病64例疗效及预后分析 被引量:8

Outcome and Prognosis in Acute Myeloid Leukemia Patients Treated with Related Peripheral Blood Hematopoietic Stem Cell Transplantation
下载PDF
导出
摘要 本研究分析亲缘外周造血干细胞移植(related peripheral blood hematopoietic stem cell transplantation)治疗急性髓系白血病(AML)的疗效及影响疗效的相关因素。对2008年4月-2011年12月在本院进行亲缘PBHSCT的AML患者64例进行回顾性分析,计算其总生存率(OS)、无白血病生存率(leukemia-free survival,LFS)和累积复发率(relapse rate,RR),并对影响疗效的因素进行统计学分析。结果表明,3年OS及LFS分别为61.9%%及52%,累积复发率为39.1%。急性移植物抗宿主病(aGVHD)的总发生率为37.5%,其中Ⅱ-Ⅳ度aGVHD发生率为29.7%。单因素分析显示,移植前疾病疗效(P=0.001)、移植供体类型(P=0.002)、初诊时白细胞数量(P=0.018)与OS相关。重度aGVHD(Ⅱ度以上aGVHD)对于OS有一定影响(P=0.070)。多因素分析显示,移植前疗效、移植供体类型、重度aGVHD是影响亲缘PBHSCT治疗AML疗效的独立预后因素。结论:亲缘PBHSCT是治疗AML的有效方法,复发是移植治疗后失败的主要原因,移植前疾病的治疗疗效、移植供体类型、重度aGVHD是独立预后因素。 This study was purposed to evaluate the outcome of acute myeloid leukemia patients treated with related peripheral blood hematopoietic stem cell transplantation (PBHSCT) and analyse the potential prognostic factors. A total of 64 acute myeloid leukemia patients treated with related peripheral allo-HSCT from march 2008 to august 2012 in our hospital were enrolled in the analysis. All the patients received either HLA-matehed related or mismatched related donor mobilized peripheral blood stem cells. All the patients were followed up and evaluated for overall survival ( OS ), leukemia-free survival(LFS) and relapse rate (RR), and the potential prognostic factors well analyzed. The results showed that the 3 year OS , LFS and RR were 61.9%, 52% and 39. 1% respectively. Univarite analysis demonstrated that the disease status before transplantation ( P 〈 0. 01 ), donor type ( P 〈 0.01 ), white blood cell count at initial diagnosis( P 〈 0.05 ) are related with outcome, and severe aGVHD has some influence on the outcome (P 〉 0.05 ). Multivariate analysis indicated the status of disease before transplantation, donor type, severe aGVHD are the most important prognostic factors. It is concluded that the related PBHSCT is effective treatment method for AML patients, recurrence is the main reason for the failure after transplantation, disease status before transplantation, donor type, and severe aGVHD are independent prognostic factors.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2014年第2期429-433,共5页 Journal of Experimental Hematology
基金 国家自然科学基金(81270611 81170518 81370635)
关键词 急性髓系白血病 造血干细胞移植 亲缘外周造血干细胞 acute myeloid leukemia hematopoietic stem cell transplantation related peripheral blood stem cell
  • 相关文献

参考文献5

二级参考文献61

  • 1Hart DP, Peggs KS. Current status of allogeneic stem cell transplantation for treatment of hematologic malignancies[ J]. Clin Pharmacol Ther, 2007, 82 (3) : 325 - 329.
  • 2Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stern cell transplantation in the therapy of acute lymphoblastie leukemia in aduhs: an evidence-based review [ J ]. Biol Blood Marrow Transplant, 2006, 12( 1 ) : 1 -30.
  • 3Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietie stem cell transplantation as part of postremisslon therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a meta-analysis[J]. Cancer, 2006, 106(12): 2657-2663.
  • 4Stein A, Forman SJ. Allogeneic transplantation for ALL in adults [ J]. Bone Marrow Transplant, 2008, 41 (5) : 439 - 446.
  • 5Lazarus HM, Perez WS, Klein JP, et al. Autotransplantation versus HLA-matched unrelated donor transplantation fur acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research [ J]. Br J Haematol, 2006, 132(6) : 755 -769.
  • 6Gale RP, Buchner T, Zhang M J, et al. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission[J]. Leukemia, 1996, 10 (1]): 1687 -1691.
  • 7Sierra .l, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience[J]. Bone Marrow Transplant, 2000, 26(4): 397-404.
  • 8Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblasfic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial ( MRC UKALLXII/ECOG E2993)[J]. Blood, 2008, 111(4): 1827- 1833.
  • 9Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era[ J]. Biot Blood Marrow Transplant, 2006, 12(8) : 795 -807,
  • 10Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[ J]. N Engl J Med, 2006, 355(23) : 2408 -2417.

共引文献21

同被引文献38

引证文献8

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部